Axogen Lifts 2026 Revenue Outlook To At Least $290 Million After Third-Quarter Sales Climb 26.2%
The nerve-repair company, now free of debt, also posted $350.1 million in cash and investments and closed its BioCircuit purchase.
Axogen, which makes products surgeons use to repair damaged peripheral nerves, raised its full-year 2026 revenue forecast to at least $290 million, growth of at least 29%, after third-quarter sales rose 26.2%, according to an 8-K filed Wednesday. The guidance includes at least $7 million from BioCircuit, a company Axogen bought on October 1.
Sales up, margin down a notch
Third-quarter revenue was $75.8 million, against $60.1 million a year earlier. Gross margin slipped to 74.8% from 76.6%.
Net income was $2.3 million, or $0.04 per share, compared with $0.7 million, or $0.01 per share, a year earlier. Adjusted EBITDA reached $13.4 million, up from $9.2 million.
For the first nine months, free cash flow was $18.9 million, versus negative $5.9 million in the same period of 2025. Net income for the nine months was a loss of $18.8 million, which includes a $16.8 million loss on extinguishing debt.
CEO Michael Dale said growth across all markets "continues to validate our market development strategies."
The guidance, with and without BioCircuit
Excluding BioCircuit, Axogen expects organic revenue of at least $283 million, growth of at least 26%. It continues to expect gross margin of at least 73% and positive free cash flow for the year.
The company said year-to-date growth was broad-based across extremities, oral maxillofacial and head and neck, and breast, driven by account productivity gains above 20%, a larger sales force and better commercial insurance coverage. Commercial payer coverage for its Avance nerve graft now reaches about 96% of covered lives in the U.S., after positive decisions from Elevance and Aetna.
A debt-free balance sheet
Cash, restricted cash and investments stood at $350.1 million at September 30, up from $113.4 million at June 30. Axogen closed an upsized public offering of 5,646,500 shares for $225 million in net proceeds; $200 million funded BioCircuit and $1.9 million covered transaction expenses. A company slide says it has no debt obligations.
Axogen's portfolio includes Avance Nerve Graft, a processed human nerve allograft, plus Axoguard nerve connectors and protectors. BioCircuit developed NerveTape, a coaptation aid the company says eliminates the need for micro-suturing.
Based on positive clinical study outcomes, Axogen decided to begin prostate market development in 2027.
Axogen will host a prostate-focused investor call and webcast on November 9 at 9:00 a.m. to lay out the clinical outcomes behind that decision.
Sources
- 8-K Filing — Axogen, Inc. (AXGN) — SEC EDGAR
- Exhibit ex991axgnearningsreleaseda.htm — Axogen, Inc. 8-K exhibit — SEC EDGAR
- Exhibit axgn_q3earningsreleasepr.htm — Axogen, Inc. 8-K exhibit — SEC EDGAR
- Exhibit q32026_axgnxcorporatepre.htm — Axogen, Inc. 8-K exhibit — SEC EDGAR
- Axogen, Inc. Reports Third Quarter 2026 Financial Results — globenewswire.com